Indian Economic Survey 2025: Call for Systematic Pharma, Healthcare Deregulation, Stronger R&D Focus
The Indian Economic Survey 2025 has highlighted critical challenges and opportunities within the country’s pharmaceutical and healthcare sectors. A strong call has been made for systematic deregulation and a strategic emphasis on research and development (R&D) to foster innovation and growth.
Key Recommendations from the Survey:
1. Streamlining Regulatory Frameworks
The Economic Survey points out the need for simplifying regulatory approvals to promote faster drug development and market entry. Excessive bureaucratic hurdles are seen as a significant bottleneck that hampers the growth potential of the pharma sector.
2. Strengthening R&D Investments
A notable emphasis has been placed on enhancing R&D funding in both public and private domains. The Survey recommends incentives such as tax breaks and grants to encourage companies to invest in innovative drug discovery and cutting-edge healthcare technologies.
3. Promoting Domestic Manufacturing
The ‘Make in India’ initiative continues to play a vital role, with the Survey encouraging policies that strengthen domestic manufacturing capabilities for Active Pharmaceutical Ingredients (APIs) and medical devices.
4. Leveraging Digital Healthcare
The Survey underscores the importance of telemedicine, electronic health records (EHRs), and AI-driven diagnostics as tools to bridge the healthcare accessibility gap, especially in rural areas.
5. Fostering Global Collaborations
To stay competitive globally, India must engage in strategic partnerships with international research institutions and pharmaceutical giants.
Sectoral Impact and Future Outlook
If these recommendations are implemented, the healthcare and pharma sectors are poised for significant growth. Deregulation will likely attract more investments, while a robust R&D ecosystem can make India a global leader in innovative healthcare solutions.
Government’s Commitment
The Survey indicates a commitment to policy reforms that address long-standing industry challenges, enabling a more conducive environment for innovation, job creation, and better health outcomes for citizens.
The Economic Survey 2025 sets the stage for transformative changes in India's healthcare and pharmaceutical landscape. With the right policy interventions, India can harness its potential to emerge as a global powerhouse in healthcare innovation.
Source- Citeline
#EconomicSurvey2025 #HealthcareInnovation #PharmaGrowth #Deregulation #R&D #DigitalHealthcare #MakeInIndia #HealthTech #IndiaRising
The Indian Economic Survey 2025 has highlighted critical challenges and opportunities within the country’s pharmaceutical and healthcare sectors. A strong call has been made for systematic deregulation and a strategic emphasis on research and development (R&D) to foster innovation and growth.
Key Recommendations from the Survey:
1. Streamlining Regulatory Frameworks
The Economic Survey points out the need for simplifying regulatory approvals to promote faster drug development and market entry. Excessive bureaucratic hurdles are seen as a significant bottleneck that hampers the growth potential of the pharma sector.
2. Strengthening R&D Investments
A notable emphasis has been placed on enhancing R&D funding in both public and private domains. The Survey recommends incentives such as tax breaks and grants to encourage companies to invest in innovative drug discovery and cutting-edge healthcare technologies.
3. Promoting Domestic Manufacturing
The ‘Make in India’ initiative continues to play a vital role, with the Survey encouraging policies that strengthen domestic manufacturing capabilities for Active Pharmaceutical Ingredients (APIs) and medical devices.
4. Leveraging Digital Healthcare
The Survey underscores the importance of telemedicine, electronic health records (EHRs), and AI-driven diagnostics as tools to bridge the healthcare accessibility gap, especially in rural areas.
5. Fostering Global Collaborations
To stay competitive globally, India must engage in strategic partnerships with international research institutions and pharmaceutical giants.
Sectoral Impact and Future Outlook
If these recommendations are implemented, the healthcare and pharma sectors are poised for significant growth. Deregulation will likely attract more investments, while a robust R&D ecosystem can make India a global leader in innovative healthcare solutions.
Government’s Commitment
The Survey indicates a commitment to policy reforms that address long-standing industry challenges, enabling a more conducive environment for innovation, job creation, and better health outcomes for citizens.
The Economic Survey 2025 sets the stage for transformative changes in India's healthcare and pharmaceutical landscape. With the right policy interventions, India can harness its potential to emerge as a global powerhouse in healthcare innovation.
Source- Citeline
#EconomicSurvey2025 #HealthcareInnovation #PharmaGrowth #Deregulation #R&D #DigitalHealthcare #MakeInIndia #HealthTech #IndiaRising
Indian Economic Survey 2025: Call for Systematic Pharma, Healthcare Deregulation, Stronger R&D Focus
The Indian Economic Survey 2025 has highlighted critical challenges and opportunities within the country’s pharmaceutical and healthcare sectors. A strong call has been made for systematic deregulation and a strategic emphasis on research and development (R&D) to foster innovation and growth.
Key Recommendations from the Survey:
1. Streamlining Regulatory Frameworks
The Economic Survey points out the need for simplifying regulatory approvals to promote faster drug development and market entry. Excessive bureaucratic hurdles are seen as a significant bottleneck that hampers the growth potential of the pharma sector.
2. Strengthening R&D Investments
A notable emphasis has been placed on enhancing R&D funding in both public and private domains. The Survey recommends incentives such as tax breaks and grants to encourage companies to invest in innovative drug discovery and cutting-edge healthcare technologies.
3. Promoting Domestic Manufacturing
The ‘Make in India’ initiative continues to play a vital role, with the Survey encouraging policies that strengthen domestic manufacturing capabilities for Active Pharmaceutical Ingredients (APIs) and medical devices.
4. Leveraging Digital Healthcare
The Survey underscores the importance of telemedicine, electronic health records (EHRs), and AI-driven diagnostics as tools to bridge the healthcare accessibility gap, especially in rural areas.
5. Fostering Global Collaborations
To stay competitive globally, India must engage in strategic partnerships with international research institutions and pharmaceutical giants.
Sectoral Impact and Future Outlook
If these recommendations are implemented, the healthcare and pharma sectors are poised for significant growth. Deregulation will likely attract more investments, while a robust R&D ecosystem can make India a global leader in innovative healthcare solutions.
Government’s Commitment
The Survey indicates a commitment to policy reforms that address long-standing industry challenges, enabling a more conducive environment for innovation, job creation, and better health outcomes for citizens.
The Economic Survey 2025 sets the stage for transformative changes in India's healthcare and pharmaceutical landscape. With the right policy interventions, India can harness its potential to emerge as a global powerhouse in healthcare innovation.
Source- Citeline
#EconomicSurvey2025 #HealthcareInnovation #PharmaGrowth #Deregulation #R&D #DigitalHealthcare #MakeInIndia #HealthTech #IndiaRising
